Stocks and Investing
Stocks and Investing
Wed, March 20, 2013
[ 07:46 AM ] - WOPRAI
[ 07:46 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 07:45 AM ] - WOPRAI
[ 07:01 AM ] - Market Wire
[ 06:30 AM ] - Market Wire
[ 05:45 AM ] - WOPRAI
[ 05:00 AM ] - Market Wire
[ 03:47 AM ] - WOPRAI
[ 03:47 AM ] - WOPRAI
[ 03:47 AM ] - WOPRAI
[ 03:46 AM ] - WOPRAI
[ 03:46 AM ] - WOPRAI
[ 03:45 AM ] - WOPRAI
[ 03:45 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andrew Peters Maintained (BMRN) at Hold with Increased Target to $59 on, Mar 20th, 2013
Andrew Peters of Deutsche Bank, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Hold with Increased Target from $45 to $59 on, Mar 20th, 2013.
Andrew has made no other calls on BMRN in the last 4 months.
There are 2 other peers that have a rating on BMRN. Out of the 2 peers that are also analyzing BMRN, 0 agree with Andrew's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Andrew
- Michelle Gilson of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $71 on, Tuesday, February 12th, 2013
- Martin Auster of "UBS" Maintained at Strong Buy with Increased Target to $67 on, Friday, February 1st, 2013